Curis, Inc. and its collaborator Genentech granted a license to Roche for rights (outside the U.S.) to GDC-0449, an oral small molecule Hedgehog pathway inhibitor. Roche, through a previous agreement with Genentech, had an option to obtain a license to commercialize certain Genentech products in non-U.S. markets.     “We are pleased with Roche’s exercise of its option to license ex-U.S. rights to GDC-0449 from Genentech. We believe the collaborative worldwide development activities of Genente...